妇科肿瘤免疫检查点抑制剂临床应用指南  

Clinical Practice Guidelines for Immune Checkpoint Inhibitor Therapy in Gynecological Tumors

作　　者：中华医学会妇科肿瘤学分会 孔北华[2] 刘继红[3] 谢幸[4] 马丁[5] 高云 高庆蕾 宋坤[8] 王登凤[9] 陈丽莉[4] 蒋芳[10] 张国楠[9] 向阳[10] Gynecological Oncology Society of Chinese Medical Association;KONG Beihua;LIU Jihong;XIE Xing;MA Ding(不详;Department of Obstetrics and Gynecology,Qilu Hospital of Shandong University,Jinan 250012,China;Department of Gynecologic Oncology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Women's Hopital,School of Medicine Zhejiang University,Hangzhou 310006,China;Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College,Huazhong University of Science&Technology,Wuhan 430030,China)

机构地区：[1]不详 [2]山东大学齐鲁医院妇产科,济南250012 [3]中山大学肿瘤防治中心妇科,广州510060 [4]浙江大学医学院附属妇产科医院,杭州310006 [5]华中科技大学同济医学院附属同济医院妇产科,武汉430030 [6]中山大学肿瘤防治中心 [7]华中科技大学同济医学院附属同济医院 [8]山东大学齐鲁医院 [9]四川省肿瘤医院/四川省第二人民医院 [10]中国医学科学院北京协和医院

出　　处：《协和医学杂志》2021年第6期854-880,共27页Medical Journal of Peking Union Medical College Hospital

摘　　要：免疫检查点抑制剂(immunecheckpointinhibitor,ICI)在部分妇科恶性肿瘤患者中显示出一定的临床疗效,目前主要用于晚期和复发性癌经常规治疗失败的患者。在三大妇科恶性肿瘤中,以子宫内膜癌疗效最好,其次是子宫颈癌,卵巢癌疗效最差。对于复发耐药的滋养细胞肿瘤患者应用ICI治疗,部分患者可取得显著疗效。应用ICI治疗,应重视筛选治疗优势人群和合理的疗效评估,早期识别、及时干预免疫治疗相关不良事件。目前ICI单药治疗妇科肿瘤临床疗效有限,联合治疗有望提高其疗效。Immune checkpoint inhibitors(ICI)have shown efficacy for some patients with gynecological tumors,which are mainly used to treat persistent,recurrent,or metastatic patients.Immunotherapy with ICI has shown good objective responses and survival benefit in patients with endometrial cancer.However,the rate of response to immunotherapy in patients with ovarian cancer remains modest.Some patients with recurrent or resistant gestational trophoblastic neoplasia benefit from ICI.ICI often has optimal duration of response.Accurately evaluating the indications and responses,recognizing and managing immune-related adverse events are essential to ICI treatment.With regards to ICI,the clinical benefit of monotherapy is limited;however,combinations of ICI with other therapies may have clinical benefit.

关 键 词：免疫检查点抑制剂 妇科肿瘤 临床应用 

分 类 号：R737.3[医药卫生—肿瘤] R730.53[医药卫生—临床医学]